June 18, 2018 / 12:32 PM / in 6 months

BUZZ-Valeant: Drops after FDA declines to approve skin disorder treatment

** Canadian drugmaker’s U.S.-listed shares down 5.4 pct at $25.45 premarket

** U.S. health regulators had declined to approve duobrii, company’s lotion to treat plaque psoriasis, citing questions related to certain data

** Psoriasis, which manifests most often as plaque psoriasis, is a chronic, relapsing, inflammatory skin disorder

** Stock has gained ~30 pct this year (Reporting by Amy Caren Daniel in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below